Opinion

Video

The Future of AYA ALL

Author(s):

Michael R. Grunwald, MD, FACPKelly Weaver, NP, DNP

The panel concludes its discussion with a look at the future of AYA ALL treatment and the role of clinical trials and innovative therapies in improving outcomes for patients.

Video content above is prompted by the following:

  • Discuss the role of clinical trials and innovative therapies in improving outcomes for patients with AYA ALL.
Related Videos
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
1 KOL is featured in this series.
Grzegorz S. Nowakowski, MD
John Seymour, MBBS, FRACP, PhD
3 KOLs are featured in this series.
Related Content
Michael Marrone, PhD, MPH
September 10th 2024

Real-World Data for Pacritinib Show Improvement in Thrombocytopenia, Anemia in Myelofibrosis

Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute
May 13th 2024

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

Jason R. Westin, MD, of The University of Texas MD Anderson Cancer Center
September 7th 2024

Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

William G. Wierda, MD, PhD
September 6th 2024

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

Stefan K. Barta, MD, MS
September 6th 2024

Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL